Does POLATUZUMAB VEDOTIN Cause Hypertransaminasaemia? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Hypertransaminasaemia have been filed in association with POLATUZUMAB VEDOTIN (POLIVY). This represents 0.1% of all adverse event reports for POLATUZUMAB VEDOTIN.
5
Reports of Hypertransaminasaemia with POLATUZUMAB VEDOTIN
0.1%
of all POLATUZUMAB VEDOTIN reports
2
Deaths
3
Hospitalizations
How Dangerous Is Hypertransaminasaemia From POLATUZUMAB VEDOTIN?
Of the 5 reports, 2 (40.0%) resulted in death, 3 (60.0%) required hospitalization.
Is Hypertransaminasaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for POLATUZUMAB VEDOTIN. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does POLATUZUMAB VEDOTIN Cause?
Disease progression (1,131)
Off label use (692)
Anaemia (344)
Blood lactate dehydrogenase increased (307)
Drug ineffective (305)
Neutropenia (303)
Death (295)
Covid-19 (286)
Febrile neutropenia (286)
Pyrexia (285)
What Other Drugs Cause Hypertransaminasaemia?
METHOTREXATE (436)
ACETAMINOPHEN (326)
PACLITAXEL (318)
CARBOPLATIN (304)
PEMBROLIZUMAB (231)
ATORVASTATIN (207)
CYCLOPHOSPHAMIDE (202)
PREDNISONE (198)
GEMCITABINE (196)
DEXAMETHASONE (169)
Which POLATUZUMAB VEDOTIN Alternatives Have Lower Hypertransaminasaemia Risk?
POLATUZUMAB VEDOTIN vs POLATUZUMAB VEDOTIN-PIIQ
POLATUZUMAB VEDOTIN vs POLIDOCANOL
POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL
POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL 3350
POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL 3350\POTASSIUM\SODIUM BICARBONATE\SODIUM